2019
DOI: 10.24287/1726-1708-2019-18-2-83-91
|View full text |Cite
|
Sign up to set email alerts
|

Brentuximab vedotin in the treatment of children and adolescents with refractory and relapsed Hodgkin's lymphoma

Abstract: Children and adolescents with refractory or relapsed Hodgkin's lymphoma (R-R HL) have unfavorable prognosis if ≥ 3 lines of therapies have to be used. New strategies based on innovative approaches are crucial for this group of patients. Nowadays immunotherapy for oncological diseases is the most promising and actively developing area. Brentuximab vedotin (BV) is efficient in adults with HL. Data in children are limited to pilot studies that are focused on response to treatment without analysis of survival. The… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

0
0
0

Year Published

2022
2022
2022
2022

Publication Types

Select...
1

Relationship

0
1

Authors

Journals

citations
Cited by 1 publication
references
References 26 publications
0
0
0
Order By: Relevance